How does atorvastatin block HMG‑CoA reductase?
Atorvastatin inhibits HMG‑CoA reductase by acting as a structural “statin-like” competitive inhibitor of the enzyme that normally converts HMG‑CoA into mevalonate, a key early step in cholesterol synthesis in the liver. By occupying the enzyme’s active site, atorvastatin reduces mevalonate production, which lowers downstream cholesterol formation.
What happens to cholesterol synthesis when mevalonate drops?
When HMG‑CoA reductase is inhibited, the pathway’s output (mevalonate and subsequent sterol/cholesterol intermediates) decreases. The liver then compensates by increasing LDL receptor activity, pulling more LDL cholesterol out of the blood. This mechanism is why statins lower circulating LDL cholesterol.
Does atorvastatin need to be converted to an active form?
Atorvastatin is administered as a prodrug and is metabolized in the body to its active statin forms that can inhibit HMG‑CoA reductase.
How specific is this inhibition, and is it reversible?
Statin inhibition of HMG‑CoA reductase is competitive and reversible: the drug reduces enzyme activity by competing with the natural substrate (HMG‑CoA) rather than permanently damaging the enzyme.
Why does blocking an enzyme early in cholesterol synthesis have a big effect?
HMG‑CoA reductase is the rate-limiting step in the cholesterol biosynthetic pathway. Blocking that step strongly reduces overall cholesterol production, which then triggers increased clearance of LDL from the bloodstream via LDL receptors.
Sources
No external sources were provided with the question.